402 related articles for article (PubMed ID: 25171160)
1. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
[TBL] [Abstract][Full Text] [Related]
2. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
Arcieri R; Germinario EA; Bonati M; Masi G; Zuddas A; Vella S; Chiarotti F; Panei P;
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
Schwartz S; Correll CU
J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):174-87. PubMed ID: 24472252
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
7. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
Panei P; Arcieri R
Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
9. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
12. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
[TBL] [Abstract][Full Text] [Related]
13. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
Germinario EA; Arcieri R; Bonati M; Zuddas A; Masi G; Vella S; Chiarotti F; Panei P;
J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):440-7. PubMed ID: 24024538
[TBL] [Abstract][Full Text] [Related]
15. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
[TBL] [Abstract][Full Text] [Related]
16. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
17. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
20. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.
Davies M; Coughtrie A; Layton D; Shakir SA
Eur Psychiatry; 2017 Jan; 39():11-16. PubMed ID: 27810613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]